Saturday, July 11, 2026

pharma · Henoch-Schoenlein Purpura Nephritis

Nanjing Children's Hospital

Nanjing Children's Hospital drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
1
Patents
0
Intelligence · Drug Pipeline

Nanjing Children's Hospital pipeline

Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Nanjing Children's Hospital drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

1 compounds
  1. US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist